Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker Corporation announces the delivery of two 1.2 GHz Avance nuclear magnetic resonance (NMR) spectrometers to the University of Warwick and the University of Birmingham in the UK. These advanced instruments will enhance capabilities in research areas including energy storage, biofuels, and biomolecule structures. Expected installations in 2025 aim to empower UK scientists and students with state-of-the-art research tools. This initiative supports breakthroughs in renewable energy technologies and drug discovery, specifically targeting antibiotic resistance.
Bruker Corporation (NASDAQ: BRKR) has unveiled significant advancements in bioinformatics at the 19th US HUPO conference. Key highlights include the launch of the PaSER™ Novor sequencing algorithm, enhancing immunopeptidomics with real-time results derived from over 1.7 million data points. The updated dia-PASEF data analysis features library-free TIMS DIA-NN software, improving quantification accuracy. Additionally, a partnership with Mass Dynamics introduces advanced visualization tools for 4D-Proteomics. These innovations aim to enhance proteomic workflows, particularly for small tumor biopsy samples, and are expected to facilitate faster clinical outcomes.
Gauss Fusion GmbH, established in 2022, aims to develop a European GW-class fusion power plant by 2045. The venture secured €8 million in pre-seed financing in February 2023 and emphasizes close collaboration with European research institutions, including the Max Planck Institute. Gauss Fusion seeks to accelerate fusion energy development through a public-private partnership model, addressing the growing energy demand while supporting a net-zero society. The initiative has garnered political attention following breakthroughs in fusion energy, with expectations of industrial partnerships to enhance its goals.
Bruker Corporation (NASDAQ: BRKR) announced that Executive Vice President and CFO Gerald Herman will present at two upcoming investor conferences. The first is the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York City on March 2, 2023, at 9:30 a.m. ET. The second is the Cowen 43rd Annual Health Care Conference in Boston, MA, scheduled for March 6, 2023, at 2:10 p.m. ET. The presentations will be available via live webcasts on the Company’s Investor Relations website, with replays accessible for 90 days following the events.
Bruker Corporation (Nasdaq: BRKR) has declared a quarterly cash dividend of $0.05 per share, set to be paid on March 17, 2023. Stockholders on record as of March 1, 2023 will receive this dividend. The company focuses on providing high-performance scientific instruments and analytical solutions, aiding in breakthroughs in life-science research and diagnostics. This dividend reflects Bruker’s commitment to returning value to shareholders while continuing to invest in innovation and customer success.
Bruker Corporation reported Q4 2022 revenues of $708.4 million, up 3.6% year-over-year, with 8.9% organic growth. GAAP EPS was $0.66, while non-GAAP EPS rose 25.4% to $0.74. For FY 2022, revenues reached $2.531 billion, marking an increase of 4.7%, and 10.2% organic growth. GAAP EPS for FY 2022 was $1.99 with a non-GAAP EPS of $2.34, up 11.4%. Looking ahead, Bruker projects FY 2023 revenues of $2.81 to $2.86 billion with non-GAAP EPS guidance of $2.52 to $2.57, indicating 8% to 10% growth.
Bruker Corporation has successfully installed two novel, compact 1.0 GHz NMR systems for structural and molecular biology applications at RIKEN in Japan and the University of Barcelona in Spain, ahead of schedule in late 2022. These Ascend Evo 1.0 GHz NMR systems operate at 4.2 Kelvin and consume approximately 65% less liquid helium compared to previous models. The compact design eases site installation and is expected to enhance research in biomolecular dynamics. The installations are already generating valuable scientific data, contributing to advancements in life sciences and clinical research.
Bruker Corporation (Nasdaq: BRKR) will report its fourth quarter and fiscal year 2022 financial results before market opening on February 9, 2023. A conference call and webcast will follow at 8:30 a.m. EST to discuss these results and current business trends. Investors can listen to the webcast at Bruker's Investor Relations website. Pre-registration for the call is available to streamline access. A replay of the conference call will be accessible from March 9, 2023, along with a slide presentation available shortly before the webcast begins.
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of ACQUIFER Imaging GmbH, enhancing its bioimaging solutions. This acquisition includes ACQUIFER's HIVE data management system, which supports high-performance computing and big-data storage for microscopy applications. Additionally, the IM04 Imaging Instrument expands Bruker's portfolio into high-content screening. The financial details of the deal were not disclosed, but it is expected to enhance Bruker's capabilities in life science research, particularly in organoid and stem cell studies.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
